{
  "kind": "treatment",
  "slug": "carbamazepine-tegretol",
  "type": "mood-stabilizer",
  "name": "Carbamazepine (Tegretol)",
  "summary": "An anticonvulsant and mood stabilizer used for epilepsy, trigeminal neuralgia, and bipolar disorder.",
  "description": "Carbamazepine (Tegretol) is an anticonvulsant and mood stabilizer that works primarily by blocking voltage-gated sodium channels, thereby stabilizing neuronal membranes and reducing repetitive firing. It is FDA-approved for seizure disorders, trigeminal neuralgia, and acute manic or mixed episodes of bipolar disorder. The immediate-release form allows for flexible dosing adjustments but may cause more peak-related side effects compared to extended-release versions.",
  "category": "medications/mood-stabilizers",
  "tags": [
    "anticonvulsant",
    "mood stabilizer",
    "antiepileptic",
    "neuropathic pain"
  ],
  "metadata": {
    "drug_classes": [
      "Anticonvulsant",
      "Mood Stabilizer"
    ],
    "therapeutic_categories": [
      "Bipolar Disorder",
      "Epilepsy",
      "Neuropathic Pain"
    ],
    "mechanism_categories": [
      "Other"
    ],
    "administration_routes": [
      "Oral"
    ],
    "prescription_status": "Prescription Required",
    "controlled_substance": false,
    "generic_available": true,
    "brand_names": [
      "Tegretol"
    ],
    "dea_schedule": null,
    "fda_pregnancy_category": "D",
    "age_groups": [
      "Adult",
      "Pediatric",
      "Geriatric"
    ],
    "treatment_duration": [
      "Short-term",
      "Long-term"
    ],
    "specialty_areas": [
      "Psychiatry",
      "Neurology"
    ],
    "fda_approval_year": 1974
  },
  "clinical_metadata": {
    "primary_indications": [
      "Seizures",
      "Pain",
      "Bipolar"
    ],
    "off_label_uses": [
      "Schizoaffective disorder",
      "Neuropathic pain syndromes",
      "Alcohol withdrawal"
    ],
    "contraindications": [
      "History of bone marrow depression",
      "MAOI use within 14 days",
      "Hypersensitivity to carbamazepine or tricyclic antidepressants"
    ],
    "monitoring_required": [
      "CBC",
      "Liver function tests",
      "Serum sodium",
      "Carbamazepine plasma levels"
    ],
    "efficacy_rating": {
      "bipolar-disorder": 4,
      "mania": 4,
      "overall-tolerability": 3
    }
  },
  "search_metadata": {
    "searchable_terms": [
      "carbamazepine",
      "tegretol",
      "mood stabilizer",
      "antiepileptic"
    ],
    "synonyms": [
      "tegretol immediate release",
      "carbamazepine IR"
    ],
    "common_misspellings": [
      "carbamzepine",
      "carbamezapine",
      "tegretole"
    ]
  },
  "sections": [
    {
      "type": "indications",
      "items": [
        "Epilepsy (partial and generalized tonic-clonic seizures)",
        "Trigeminal neuralgia",
        "Acute mania and maintenance in bipolar disorder"
      ]
    },
    {
      "type": "mechanism",
      "text": "Blocks voltage-gated sodium channels, reducing sustained high-frequency neuronal firing and diminishing excitatory neurotransmission."
    },
    {
      "type": "dosing",
      "adult": {
        "start": "200 mg twice daily",
        "titrate": "Increase by 200 mg/day every week as tolerated",
        "usual_range": "800–1200 mg/day in divided doses",
        "max": "1600 mg/day"
      },
      "pediatric": "10–20 mg/kg/day in divided doses",
      "geriatric": "Start at lower doses and titrate slowly",
      "hepatic_impairment": "Use with caution; monitor LFTs",
      "renal_impairment": "No major adjustment; monitor closely"
    },
    {
      "type": "dosage_forms",
      "items": [
        "Tablets: 200 mg",
        "Chewable tablets: 100 mg",
        "Oral suspension: 100 mg/5 mL"
      ]
    },
    {
      "type": "onset_duration",
      "text": "Anticonvulsant effects can be seen within days; mood stabilization may take 1–2 weeks."
    },
    {
      "type": "adverse_effects",
      "common": [
        "drowsiness",
        "dizziness",
        "nausea",
        "vomiting",
        "ataxia",
        "blurred vision"
      ],
      "less_common": [
        "rash",
        "hyponatremia",
        "mild leukopenia"
      ],
      "serious": [
        "Stevens–Johnson syndrome",
        "toxic epidermal necrolysis",
        "aplastic anemia",
        "agranulocytosis",
        "hepatic failure"
      ]
    },
    {
      "type": "warnings",
      "black_box": "Serious and sometimes fatal dermatologic reactions and aplastic anemia/agranulocytosis.",
      "other": [
        "Screen for HLA-B*1502 in patients of Asian ancestry",
        "Avoid abrupt discontinuation to prevent seizure or mood relapse"
      ]
    },
    {
      "type": "interactions",
      "items": [
        {
          "with": "MAOIs",
          "risk": "Hypertensive crisis",
          "action": "Avoid; 14-day washout"
        },
        {
          "with": "Oral contraceptives",
          "risk": "Reduced efficacy",
          "action": "Use backup contraception"
        },
        {
          "with": "Warfarin",
          "risk": "Reduced anticoagulant effect",
          "action": "Monitor INR"
        },
        {
          "with": "Other CNS depressants",
          "risk": "Additive sedation",
          "action": "Use caution"
        }
      ]
    },
    {
      "type": "monitoring",
      "items": [
        "CBC at baseline and periodically",
        "Liver function tests at baseline and periodically",
        "Serum sodium",
        "Carbamazepine plasma levels (therapeutic: 4–12 mcg/mL)"
      ]
    },
    {
      "type": "special_populations",
      "pregnancy": "Category D; teratogenic risk (e.g., neural tube defects)",
      "lactation": "Excreted in breast milk; monitor infant for sedation and feeding issues",
      "pediatrics": "Approved for seizure disorders; caution in mood disorders",
      "geriatrics": "Increased risk of hyponatremia"
    },
    {
      "type": "tapering",
      "text": "Reduce gradually over 1–2 weeks to avoid rebound seizures or mood destabilization."
    },
    {
      "type": "clinical_notes",
      "items": [
        "May induce its own metabolism (autoinduction) requiring dose adjustments after initial titration",
        "Immediate-release form may cause more peak-dose side effects than ER"
      ]
    },
    {
      "type": "references",
      "items": [
        {
          "label": "Tegretol Prescribing Information",
          "url": "https://www.accessdata.fda.gov/"
        },
        {
          "label": "Carbamazepine Clinical Review",
          "url": "https://pubmed.ncbi.nlm.nih.gov/"
        }
      ]
    }
  ],
  "seo": {
    "title": "Carbamazepine (Tegretol): Uses, Dosing, Side Effects",
    "description": "Complete guide to carbamazepine (Tegretol), including dosing, adverse effects, monitoring, and interactions."
  }
}
